查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103038

多重系統退化症症 (MSA) 療法全球研發管線分析：2026 年第二季 - 臨床試驗

Global Multiple System Atrophy Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

多重系統退化症症（MSA）是一種罕見的進行性神經退化性疾病，其特徵為自主神經功能障礙、類似帕金森氏症的症狀、小腦功能障礙和廣泛的神經功能衰退。儘管神經科學研究取得了顯著進展，但由於缺乏廣泛應用的疾病修正治療，MSA領域仍存在巨大的未滿足醫療需求。目前的治療方法主要以緩解症狀為主，因此迫切需要能夠延緩或阻止疾病進展的創新療法。

對於尋求評估未來市場機會和競爭地位的製藥公司、生技公司、投資者、醫療顧問公司和研究機構而言，藥物研發管線分析的重要性日益凸顯。本報告深入分析了臨床開發趨勢、治療標靶、分子類型、法規核准流程、策略聯盟和商業化前景。隨著我們對疾病機制（尤其是α-突觸核蛋白聚集和神經退化）的科學認知不斷加深，處於不同臨床實驗階段的療法研發正在推動多重系統退化症症（MSA）研發管線的整體擴張。

市場促進因素

人們越來越重視疾病修正治療

推動產業成長要素之一是治療方向從症狀治療轉向旨在改變潛在疾病進程的療法。研究人員正日益關注α-突觸核蛋白的累積、神經發炎、粒線體功能障礙和神經退化。

對疾病修正治療的追求促使研究活動擴展到多種治療方法，從而創造了一個更具活力和競爭性的發展環境。

孤兒藥研發的擴展

由於 MSA 在主要醫藥市場被歸類為罕見疾病，研發公司可以享有孤兒藥的優惠待遇，例如監管支援、市場獨佔權、降低費用和加速研發流程。

這些優惠措施鼓勵生物技術和製藥公司進入市場，有助於加強目前正在進行臨床實驗的治療藥物的整體研發管線。

擴大臨床試驗活動

隨著越來越多的公司將有前景的候選藥物推進到人體試驗階段，臨床開發活動持續增加。早期和中期臨床計畫的重要性日益凸顯，因為申辦者需要評估藥物的安全性、有效性、生物標記以及疾病進展等終點指標。

臨床試驗活動的擴展產生了寶貴的研發管線訊息，為整個MSA生態系統的策略性投資決策提供了支持。

疾病生物學研究進展

對多重系統退化症症（MSA）發病機制的深入了解正在加速新型治療標靶的發現。對α-突觸核蛋白病理、蛋白質聚集、神經保護路徑、發炎機制和基因調控的研究，為創新藥物的研發創造了新的機會。

這些科學進步為更廣泛的研發計畫提供了支持，並增加了未來治療取得突破性進展的可能性。

本報告分析了多重系統退化症症 (MSA) 治療的全球市場，重點關注在研藥物的研發趨勢。報告內容包括疾病概述、目前治療現狀、按研發階段、分子類型、給藥途徑和作用機制等不同類別對在研藥物進行分析、區域/主要國家趨勢、競爭格局、主要公司簡介以及未來展望。

目錄

第1章執行摘要

第2章 疾病概述

  • 多重系統退化症症 (MSA)：概述
  • 疾病的病理生理學
  • 疾病分類
    • 帕金森型多重系統退化症症（MSA-P）
    • 小腦多重系統退化症症（MSA-C）
  • 疾病進展和臨床症狀
  • 目前的標準治療
  • 未滿足的醫療需求
  • 治療挑戰

第3章：治療狀況分析

  • 目前治療模式
  • 症狀治療方法
  • 藥物治療
  • 非藥物療法
  • 新的緩解疾病策略
  • 治療流程評估
  • 未來治療趨勢

第4章：管道現狀概述

  • 流程概覽：依開發階段分類
  • 管線概覽：依分子類型分類
  • 管道概覽：按給藥途徑
  • 管線概覽：依作用機轉分類
  • 管道概覽：依公司類型分類
  • 暫停中和終止的項目
  • 有前途的臨床候選者
  • 未來創新領域

第5章：臨床試驗現況分析

  • 臨床試驗摘要
  • 臨床試驗：依研發階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 臨床試驗：按地區
  • 臨床試驗：依申辦單位類型
  • 臨床試驗：按患者族群
  • 臨床試驗終點分析
  • 參與者招募和註冊的趨勢
  • 對正在進行的臨床試驗的評估
  • 對已完成的臨床試驗的評估
  • 即將到來的重要臨床里程碑

第6章 管道分析：按細分市場

  • 按發展階段
    • 發現
    • 臨床前
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
    • 監理階段
  • 依分子類型
    • 小分子藥物
    • 單株抗體
    • 反義寡核苷酸
    • 基因治療
    • 細胞療法
    • 胜肽
    • 其他新模式
  • 透過行政途徑
    • 口服
    • 靜脈
    • 皮下
    • 鞘內腔
    • 鼻內
    • 其他給藥途徑
  • 透過作用機制
    • 針對α-突觸核蛋白的療法
    • 神經保護療法
    • 抗發炎治療
    • 蛋白質聚集抑制劑
    • 基因療法
    • 細胞療法
    • 自主神經系統功能障礙的治療方法
    • 其他新型作用機制

第7章：競爭資訊分析

  • 競爭格局概述
  • 企業基準分析
  • 管道強度評估
  • 臨床開發階段的定位
  • 創新指數評估
  • 策略聯盟與夥伴關係
  • 授權和收購趨勢
  • 資金籌措和投資趨勢
  • 新興創新者分析
  • 未來競爭環境展望

第8章 臨床試驗的區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 目前正在進行的臨床試驗
    • 研究基礎設施
    • 法規環境
    • 研究者網路分析
    • 未來成長機遇

第9章：主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第10章：主要藥物概況

  • ATH434
  • Verdiperstat
  • Lu AF82422
  • Ampreloxetine
    • 藥物概述
    • 作用機制
    • 臨床開發狀態
    • 臨床試驗結果
    • 安全概況
    • 未來發展計劃

第11章：公司簡介

  • Alterity Therapeutics Limited
  • Biohaven Ltd.
  • Lundbeck A/S
  • Neurocrine Biosciences, Inc.
  • AbbVie Inc.
  • UCB SA
  • Ionis Pharmaceuticals, Inc.
  • Prothena Corporation plc
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Roche Holding AG
  • AstraZeneca PLC

第12章：合夥、許可與併購分析

  • 策略聯盟
  • 授權協議
  • 聯合發展夥伴關係
  • 研究夥伴關係
  • 併購活動
  • 投資趨勢
  • 未來合作機會

第13章：未來展望與機會評估

  • 未來管道演進
  • 下一代治療方法
  • 疾病修正治療的前景
  • 商業機會評估
  • 臨床開發前景
  • 發展因素
  • 未來市場進入機會

第14章調查方法

第15章附錄

簡介目錄
Product Code: KSI-008829

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonian symptoms, cerebellar impairment, and widespread neurological deterioration. Despite significant advances in neuroscience research, MSA remains an area of substantial unmet medical need due to the absence of widely available disease-modifying treatments. Current therapeutic approaches are largely focused on symptomatic management, creating strong demand for innovative therapies capable of slowing or preventing disease progression.

Drug pipeline analysis has become increasingly important for pharmaceutical companies, biotechnology firms, investors, healthcare consultants, and research organizations seeking to evaluate future market opportunities and competitive positioning. Pipeline intelligence provides insights into clinical development trends, therapeutic targets, molecule types, regulatory pathways, strategic collaborations, and commercialization prospects. Growing scientific understanding of disease mechanisms, particularly alpha-synuclein aggregation and neurodegeneration, is supporting the development of a diverse range of investigational therapies and expanding the overall MSA pipeline landscape.

Market Drivers

Increasing Focus on Disease-Modifying Therapies

One of the primary growth drivers is the industry's transition from symptomatic treatment approaches toward therapies designed to modify the underlying disease process. Researchers are increasingly targeting alpha-synuclein accumulation, neuroinflammation, mitochondrial dysfunction, and neuronal degeneration.

The pursuit of disease-modifying interventions has expanded research activity across multiple therapeutic modalities, creating a more dynamic and competitive development environment.

Expansion of Orphan Drug Development

MSA qualifies as a rare disease in major pharmaceutical markets, allowing developers to benefit from orphan drug incentives such as regulatory support, market exclusivity, fee reductions, and accelerated development pathways.

These incentives are encouraging greater participation from biotechnology and pharmaceutical companies and are helping to strengthen the overall pipeline of investigational therapies.

Growing Clinical Trial Activity

Clinical development activity continues to increase as more companies advance promising candidates into human studies. Early-stage and mid-stage clinical programs are becoming increasingly important as sponsors evaluate safety, efficacy, biomarkers, and disease progression endpoints.

Growing clinical trial activity is generating valuable pipeline intelligence and supporting strategic investment decisions throughout the MSA ecosystem.

Advances in Disease Biology Research

Improved understanding of MSA pathogenesis has accelerated the identification of novel therapeutic targets. Research into alpha-synuclein pathology, protein aggregation, neuroprotective pathways, inflammatory mechanisms, and genetic regulation is creating new opportunities for innovative drug development.

These scientific advances are supporting a broader range of development programs and increasing the probability of future therapeutic breakthroughs.

Market Restraints

Limited Patient Population

As a rare disease, MSA affects a relatively small number of patients worldwide. The limited patient pool creates challenges for clinical trial recruitment, epidemiological studies, and commercial market sizing.

Recruitment difficulties may increase development timelines and costs, slowing pipeline progression.

High Clinical Development Risk

Neurodegenerative disease drug development remains associated with significant scientific uncertainty and elevated failure rates. Demonstrating meaningful clinical benefit in MSA can be challenging due to disease complexity and progression variability.

Many promising therapies may encounter difficulties during clinical evaluation, creating substantial investment risk.

Lack of Validated Biomarkers

The absence of widely accepted biomarkers and surrogate endpoints continues to complicate therapeutic assessment. Developers often rely on clinical outcome measures that require lengthy observation periods.

These limitations can increase development complexity and affect regulatory timelines.

Technology and Segment Insights

The global multiple system atrophy drug pipeline analysis market can be segmented by development stage, molecule type, mechanism of action, therapy platform, end user, and geography.

By development stage, the market includes discovery, preclinical, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and registration-stage programs. Discovery and preclinical programs account for a substantial share of pipeline activity as researchers continue identifying novel therapeutic targets. Phase II remains one of the most strategically significant segments because proof-of-concept data generated at this stage often influences future investment and partnership decisions.

By molecule type, the market includes small molecules, monoclonal antibodies, antisense oligonucleotides, gene therapies, cell therapies, peptides, and other advanced therapeutic modalities. Small molecules currently represent a significant portion of the pipeline due to established development pathways and scalable manufacturing. However, biologics, RNA-based therapies, and gene therapies are gaining momentum as developers pursue highly targeted treatment strategies.

By mechanism of action, the market includes alpha-synuclein targeting therapies, neuroprotective therapies, anti-inflammatory agents, protein aggregation inhibitors, gene-based approaches, cell-based therapies, and other emerging mechanisms. Alpha-synuclein-targeted therapies represent one of the most active development areas because protein aggregation is widely considered a central driver of disease progression.

By therapy platform, the market encompasses biologics, molecular therapeutics, RNA therapeutics, regenerative medicine, precision medicine approaches, and advanced neurological interventions. Emerging technologies are increasingly focused on addressing the root causes of disease rather than managing symptoms alone.

By end user, the market serves pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, investors, healthcare consulting firms, and competitive intelligence providers. Pharmaceutical and biotechnology companies account for a substantial share due to ongoing portfolio assessment and strategic planning activities.

Several notable investigational candidates are advancing through development, including Amlenetug, ATH434, AB-1005, Foralumab, KM-819, ION464, PMN442, and other emerging therapies targeting diverse disease pathways. The pipeline currently includes more than 20 companies and over 20 investigational products across multiple stages of development.

Technological innovation is playing an increasingly important role in pipeline development. Artificial intelligence, biomarker discovery platforms, advanced neuroimaging technologies, genomic research, and precision medicine tools are improving target identification, patient stratification, and clinical trial design. These capabilities are enhancing development efficiency and supporting more sophisticated therapeutic approaches.

Geographically, North America represents the leading market due to strong neuroscience research infrastructure, significant rare disease funding, active clinical development programs, and favorable orphan drug policies. Europe remains an important market supported by collaborative research initiatives and regulatory incentives. Asia-Pacific is expected to experience growing activity as healthcare investments increase and neurological research capabilities expand.

Competitive and Strategic Outlook

The competitive landscape is becoming increasingly dynamic as biotechnology firms and pharmaceutical companies pursue differentiated strategies for disease modification. Companies are investing heavily in alpha-synuclein-targeting therapies, neuroprotective agents, antisense technologies, gene therapies, and regenerative medicine approaches.

Strategic partnerships, licensing agreements, research collaborations, and co-development arrangements are becoming common as organizations seek to combine scientific expertise, clinical capabilities, and financial resources. Biotechnology companies continue to drive much of the innovation, while larger pharmaceutical organizations are increasingly participating through acquisitions, partnerships, and targeted investments.

Leading organizations active within the pipeline include companies such as Alterity Therapeutics, Biohaven, Lundbeck, AbbVie, Neurocrine Biosciences, Ionis Pharmaceuticals, AskBio, Ono Pharmaceutical, ProMIS Neurosciences, and several emerging biotechnology developers. Their collective efforts are expanding therapeutic diversity and strengthening the long-term outlook for MSA treatment innovation.

Conclusion

The global multiple system atrophy drug pipeline analysis market is poised for significant expansion through 2031, supported by increasing rare disease research, growing orphan drug incentives, advances in disease biology, and expanding clinical development activity. The pipeline is evolving toward mechanism-based therapies that target alpha-synuclein pathology, neurodegeneration, and disease progression. While challenges related to patient recruitment, biomarker development, and clinical risk remain, ongoing innovation across small molecules, biologics, antisense therapies, gene therapies, and regenerative medicine platforms is expected to create substantial opportunities for stakeholders throughout the MSA therapeutic ecosystem.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Scope and Objectives
  • 1.2 Key Findings
  • 1.3 Pipeline Landscape Overview
  • 1.4 Clinical Development Highlights
  • 1.5 Key Emerging Therapies
  • 1.6 Competitive Intelligence Snapshot
  • 1.7 Future Outlook

2. Disease Overview

  • 2.1 Introduction to Multiple System Atrophy (MSA)
  • 2.2 Disease Pathophysiology
  • 2.3 Disease Classification
    • 2.3.1 Multiple System Atrophy-Parkinsonian Type (MSA-P)
    • 2.3.2 Multiple System Atrophy-Cerebellar Type (MSA-C)
  • 2.4 Disease Progression and Clinical Manifestations
  • 2.5 Current Standard of Care
  • 2.6 Unmet Medical Needs
  • 2.7 Treatment Challenges

3. Treatment Landscape Analysis

  • 3.1 Current Treatment Paradigm
  • 3.2 Symptomatic Treatment Approaches
  • 3.3 Pharmacological Therapies
  • 3.4 Non-Pharmacological Management
  • 3.5 Emerging Disease-Modifying Strategies
  • 3.6 Treatment Algorithm Assessment
  • 3.7 Future Treatment Trends

4. Pipeline Landscape Overview

  • 4.1 Pipeline Snapshot by Development Stage
  • 4.2 Pipeline Snapshot by Molecule Type
  • 4.3 Pipeline Snapshot by Route of Administration
  • 4.4 Pipeline Snapshot by Mechanism of Action
  • 4.5 Pipeline Snapshot by Company Type
  • 4.6 Dormant and Discontinued Programs
  • 4.7 Promising Clinical Candidates
  • 4.8 Future Innovation Areas

5. Clinical Trials Landscape Analysis

  • 5.1 Clinical Trial Overview
  • 5.2 Clinical Trials by Development Phase
    • 5.2.1 Phase I
    • 5.2.2 Phase I/II
    • 5.2.3 Phase II
    • 5.2.4 Phase II/III
    • 5.2.5 Phase III
  • 5.3 Clinical Trials by Geography
  • 5.4 Clinical Trials by Sponsor Type
  • 5.5 Clinical Trials by Patient Population
  • 5.6 Clinical Trial Endpoints Analysis
  • 5.7 Recruitment and Enrollment Trends
  • 5.8 Ongoing Clinical Trials Assessment
  • 5.9 Completed Clinical Trials Assessment
  • 5.10 Upcoming Clinical Milestones

6. Pipeline Segmentation Analysis

  • 6.1 By Development Stage
    • 6.1.1 Discovery
    • 6.1.2 Preclinical
    • 6.1.3 Phase I
    • 6.1.4 Phase I/II
    • 6.1.5 Phase II
    • 6.1.6 Phase II/III
    • 6.1.7 Phase III
    • 6.1.8 Regulatory Stage
  • 6.2 By Molecule Type
    • 6.2.1 Small Molecules
    • 6.2.2 Monoclonal Antibodies
    • 6.2.3 Antisense Oligonucleotides
    • 6.2.4 Gene Therapies
    • 6.2.5 Cell Therapies
    • 6.2.6 Peptides
    • 6.2.7 Other Novel Modalities
  • 6.3 By Route of Administration
    • 6.3.1 Oral
    • 6.3.2 Intravenous
    • 6.3.3 Subcutaneous
    • 6.3.4 Intrathecal
    • 6.3.5 Intranasal
    • 6.3.6 Other Routes
  • 6.4 By Mechanism of Action
    • 6.4.1 Alpha-Synuclein Targeting Therapies
    • 6.4.2 Neuroprotective Therapies
    • 6.4.3 Anti-Inflammatory Therapies
    • 6.4.4 Protein Aggregation Inhibitors
    • 6.4.5 Gene-Based Therapies
    • 6.4.6 Cell-Based Therapies
    • 6.4.7 Autonomic Dysfunction Therapies
    • 6.4.8 Other Novel Mechanisms

7. Competitive Intelligence Analysis

  • 7.1 Competitive Landscape Overview
  • 7.2 Company Benchmarking Analysis
  • 7.3 Pipeline Strength Assessment
  • 7.4 Clinical Stage Positioning
  • 7.5 Innovation Index Assessment
  • 7.6 Strategic Collaborations and Partnerships
  • 7.7 Licensing and Acquisition Activity
  • 7.8 Funding and Investment Trends
  • 7.9 Emerging Innovators Analysis
  • 7.10 Future Competitive Outlook

8. Clinical Trial Geography Analysis

  • 8.1 North America
    • 8.1.1 Active Clinical Trials
    • 8.1.2 Research Infrastructure
    • 8.1.3 Regulatory Environment
    • 8.1.4 Investigator Network Analysis
    • 8.1.5 Future Growth Opportunities
  • 8.2 Europe
    • 8.2.1 Active Clinical Trials
    • 8.2.2 Research Infrastructure
    • 8.2.3 Regulatory Environment
    • 8.2.4 Investigator Network Analysis
    • 8.2.5 Future Growth Opportunities
  • 8.3 Asia-Pacific
    • 8.3.1 Active Clinical Trials
    • 8.3.2 Research Infrastructure
    • 8.3.3 Regulatory Environment
    • 8.3.4 Investigator Network Analysis
    • 8.3.5 Future Growth Opportunities
  • 8.4 Latin America
    • 8.4.1 Active Clinical Trials
    • 8.4.2 Research Infrastructure
    • 8.4.3 Regulatory Environment
    • 8.4.4 Investigator Network Analysis
    • 8.4.5 Future Growth Opportunities
  • 8.5 Middle East & Africa
    • 8.5.1 Active Clinical Trials
    • 8.5.2 Research Infrastructure
    • 8.5.3 Regulatory Environment
    • 8.5.4 Investigator Network Analysis
    • 8.5.5 Future Growth Opportunities

9. Key Countries Analysis

  • 9.1 United States
    • 9.1.1 Active Clinical Trials
    • 9.1.2 Key Sponsors
    • 9.1.3 Research Infrastructure
    • 9.1.4 Regulatory Environment
    • 9.1.5 Funding Trends
    • 9.1.6 Investigator Activity
    • 9.1.7 Future Growth Opportunities
  • 9.2 Canada
    • 9.2.1 Active Clinical Trials
    • 9.2.2 Key Sponsors
    • 9.2.3 Research Infrastructure
    • 9.2.4 Regulatory Environment
    • 9.2.5 Funding Trends
    • 9.2.6 Investigator Activity
    • 9.2.7 Future Growth Opportunities
  • 9.3 Germany
    • 9.3.1 Active Clinical Trials
    • 9.3.2 Key Sponsors
    • 9.3.3 Research Infrastructure
    • 9.3.4 Regulatory Environment
    • 9.3.5 Funding Trends
    • 9.3.6 Investigator Activity
    • 9.3.7 Future Growth Opportunities
  • 9.4 United Kingdom
    • 9.4.1 Active Clinical Trials
    • 9.4.2 Key Sponsors
    • 9.4.3 Research Infrastructure
    • 9.4.4 Regulatory Environment
    • 9.4.5 Funding Trends
    • 9.4.6 Investigator Activity
    • 9.4.7 Future Growth Opportunities
  • 9.5 France
    • 9.5.1 Active Clinical Trials
    • 9.5.2 Key Sponsors
    • 9.5.3 Research Infrastructure
    • 9.5.4 Regulatory Environment
    • 9.5.5 Funding Trends
    • 9.5.6 Investigator Activity
    • 9.5.7 Future Growth Opportunities
  • 9.6 Italy
    • 9.6.1 Active Clinical Trials
    • 9.6.2 Key Sponsors
    • 9.6.3 Research Infrastructure
    • 9.6.4 Regulatory Environment
    • 9.6.5 Funding Trends
    • 9.6.6 Investigator Activity
    • 9.6.7 Future Growth Opportunities
  • 9.7 Spain
    • 9.7.1 Active Clinical Trials
    • 9.7.2 Key Sponsors
    • 9.7.3 Research Infrastructure
    • 9.7.4 Regulatory Environment
    • 9.7.5 Funding Trends
    • 9.7.6 Investigator Activity
    • 9.7.7 Future Growth Opportunities
  • 9.8 China
    • 9.8.1 Active Clinical Trials
    • 9.8.2 Key Sponsors
    • 9.8.3 Research Infrastructure
    • 9.8.4 Regulatory Environment
    • 9.8.5 Funding Trends
    • 9.8.6 Investigator Activity
    • 9.8.7 Future Growth Opportunities
  • 9.9 Japan
    • 9.9.1 Active Clinical Trials
    • 9.9.2 Key Sponsors
    • 9.9.3 Research Infrastructure
    • 9.9.4 Regulatory Environment
    • 9.9.5 Funding Trends
    • 9.9.6 Investigator Activity
    • 9.9.7 Future Growth Opportunities
  • 9.10 India
    • 9.10.1 Active Clinical Trials
    • 9.10.2 Key Sponsors
    • 9.10.3 Research Infrastructure
    • 9.10.4 Regulatory Environment
    • 9.10.5 Funding Trends
    • 9.10.6 Investigator Activity
    • 9.10.7 Future Growth Opportunities

10. Key Drug Profiles

  • 10.1 ATH434
    • 10.1.1 Drug Overview
    • 10.1.2 Mechanism of Action
    • 10.1.3 Clinical Development Status
    • 10.1.4 Clinical Trial Results
    • 10.1.5 Safety Profile
    • 10.1.6 Future Development Plans
  • 10.2 Verdiperstat
    • 10.2.1 Drug Overview
    • 10.2.2 Mechanism of Action
    • 10.2.3 Clinical Development Status
    • 10.2.4 Clinical Trial Results
    • 10.2.5 Safety Profile
    • 10.2.6 Future Development Plans
  • 10.3 Lu AF82422
    • 10.3.1 Drug Overview
    • 10.3.2 Mechanism of Action
    • 10.3.3 Clinical Development Status
    • 10.3.4 Clinical Trial Results
    • 10.3.5 Safety Profile
    • 10.3.6 Future Development Plans
  • 10.4 Ampreloxetine
    • 10.4.1 Drug Overview
    • 10.4.2 Mechanism of Action
    • 10.4.3 Clinical Development Status
    • 10.4.4 Clinical Trial Results
    • 10.4.5 Safety Profile
    • 10.4.6 Future Development Plans

11. Company Profiles

  • 11.1 Alterity Therapeutics Limited
    • 11.1.1 Overview
    • 11.1.2 Financials
    • 11.1.3 MSA Pipeline Portfolio
    • 11.1.4 Clinical Development Strategy
    • 11.1.5 Key Drug Candidates
    • 11.1.6 Clinical Trial Programs
    • 11.1.7 Strategic Collaborations
    • 11.1.8 Recent Developments
  • 11.2 Biohaven Ltd.
    • 11.2.1 Overview
    • 11.2.2 Financials
    • 11.2.3 MSA Pipeline Portfolio
    • 11.2.4 Clinical Development Strategy
    • 11.2.5 Key Drug Candidates
    • 11.2.6 Clinical Trial Programs
    • 11.2.7 Strategic Collaborations
    • 11.2.8 Recent Developments
  • 11.3 Lundbeck A/S
    • 11.3.1 Overview
    • 11.3.2 Financials
    • 11.3.3 MSA Pipeline Portfolio
    • 11.3.4 Clinical Development Strategy
    • 11.3.5 Key Drug Candidates
    • 11.3.6 Clinical Trial Programs
    • 11.3.7 Strategic Collaborations
    • 11.3.8 Recent Developments
  • 11.4 Neurocrine Biosciences, Inc.
    • 11.4.1 Overview
    • 11.4.2 Financials
    • 11.4.3 MSA Pipeline Portfolio
    • 11.4.4 Clinical Development Strategy
    • 11.4.5 Key Drug Candidates
    • 11.4.6 Clinical Trial Programs
    • 11.4.7 Strategic Collaborations
    • 11.4.8 Recent Developments
  • 11.5 AbbVie Inc.
    • 11.5.1 Overview
    • 11.5.2 Financials
    • 11.5.3 MSA Pipeline Portfolio
    • 11.5.4 Clinical Development Strategy
    • 11.5.5 Key Drug Candidates
    • 11.5.6 Clinical Trial Programs
    • 11.5.7 Strategic Collaborations
    • 11.5.8 Recent Developments
  • 11.6 UCB S.A.
    • 11.6.1 Overview
    • 11.6.2 Financials
    • 11.6.3 MSA Pipeline Portfolio
    • 11.6.4 Clinical Development Strategy
    • 11.6.5 Key Drug Candidates
    • 11.6.6 Clinical Trial Programs
    • 11.6.7 Strategic Collaborations
    • 11.6.8 Recent Developments
  • 11.7 Ionis Pharmaceuticals, Inc.
    • 11.7.1 Overview
    • 11.7.2 Financials
    • 11.7.3 MSA Pipeline Portfolio
    • 11.7.4 Clinical Development Strategy
    • 11.7.5 Key Drug Candidates
    • 11.7.6 Clinical Trial Programs
    • 11.7.7 Strategic Collaborations
    • 11.7.8 Recent Developments
  • 11.8 Prothena Corporation plc
    • 11.8.1 Overview
    • 11.8.2 Financials
    • 11.8.3 MSA Pipeline Portfolio
    • 11.8.4 Clinical Development Strategy
    • 11.8.5 Key Drug Candidates
    • 11.8.6 Clinical Trial Programs
    • 11.8.7 Strategic Collaborations
    • 11.8.8 Recent Developments
  • 11.9 Takeda Pharmaceutical Company Limited
    • 11.9.1 Overview
    • 11.9.2 Financials
    • 11.9.3 MSA Pipeline Portfolio
    • 11.9.4 Clinical Development Strategy
    • 11.9.5 Key Drug Candidates
    • 11.9.6 Clinical Trial Programs
    • 11.9.7 Strategic Collaborations
    • 11.9.8 Recent Developments
  • 11.10 Biogen Inc.
    • 11.10.1 Overview
    • 11.10.2 Financials
    • 11.10.3 MSA Pipeline Portfolio
    • 11.10.4 Clinical Development Strategy
    • 11.10.5 Key Drug Candidates
    • 11.10.6 Clinical Trial Programs
    • 11.10.7 Strategic Collaborations
    • 11.10.8 Recent Developments
  • 11.11 Roche Holding AG
    • 11.11.1 Overview
    • 11.11.2 Financials
    • 11.11.3 MSA Pipeline Portfolio
    • 11.11.4 Clinical Development Strategy
    • 11.11.5 Key Drug Candidates
    • 11.11.6 Clinical Trial Programs
    • 11.11.7 Strategic Collaborations
    • 11.11.8 Recent Developments
  • 11.12 AstraZeneca PLC
    • 11.12.1 Overview
    • 11.12.2 Financials
    • 11.12.3 MSA Pipeline Portfolio
    • 11.12.4 Clinical Development Strategy
    • 11.12.5 Key Drug Candidates
    • 11.12.6 Clinical Trial Programs
    • 11.12.7 Strategic Collaborations
    • 11.12.8 Recent Developments

12. Partnership, Licensing and M&A Analysis

  • 12.1 Strategic Collaborations
  • 12.2 Licensing Agreements
  • 12.3 Co-Development Partnerships
  • 12.4 Research Alliances
  • 12.5 Merger and Acquisition Activity
  • 12.6 Investment Trends
  • 12.7 Future Partnership Opportunities

13. Future Outlook and Opportunity Assessment

  • 13.1 Future Pipeline Evolution
  • 13.2 Next-Generation Therapeutic Approaches
  • 13.3 Disease-Modifying Therapy Outlook
  • 13.4 Commercial Opportunity Assessment
  • 13.5 Clinical Development Outlook
  • 13.6 Key Upcoming Catalysts
  • 13.7 Future Market Entry Opportunities

14. Research Methodology

  • 14.1 Primary Research
  • 14.2 Secondary Research
  • 14.3 Pipeline Assessment Methodology
  • 14.4 Clinical Trial Assessment Methodology
  • 14.5 Data Validation and Triangulation
  • 14.6 Assumptions and Limitations

15. Appendix

  • 15.1 Abbreviations
  • 15.2 Glossary of Terms
  • 15.3 References
  • 15.4 List of Tables
  • 15.5 List of Figures
  • 15.6 Clinical Trial Databases Reviewed
  • 15.7 Company Information Sourc